Exodus Point Capital Management, LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.84 - $9.74 $50,918 - $129,152	-13,260 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$5.12 - $8.19 $1,827 - $2,923	357 Added 2.77%	13,260 $69,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $86,192 - $117,417	12,903 New	12,903 $86,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $9.23 $146,757 - $173,219	-18,767 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$8.44 - $12.66 $158,393 - $237,590	18,767 New	18,767 $166,000

Q2 2019 Aug 14, 2019	SELL	$9.54 - $14.96 $370,400 - $580,836	-38,826 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$10.31 - $14.38 $251,832 - $351,245	24,426 Added 169.63%	38,826 $543,000
Q4 2018 Feb 14, 2019	BUY	$8.63 - $12.4 $124,272 - $178,560	14,400 New	14,400 $146,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.